Dyslipidemia in Obesity: Mechanisms and Potential Targets
Open accessThe DOI matches its Crossref record; 166 of the 169 references it cites were found in a registry or an index; 5 of the 56 sources its claims cite were checked for support.
Abstract
Obesity has become a major worldwide health problem. In every single country in the world, the incidence of obesity is rising continuously and therefore, the associated morbidity, mortality and both medical and economical costs are expected to increase as well. The majority of these complications are related to co-morbid conditions that include coronary artery disease, hypertension, type 2 diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases cardiovascular risk through risk factors such as increased fasting plasma triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk factors associated to obesity are the presence of the small dense LDL phenotype, postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic overproduction of apoB containing lipoproteins. All these lipid abnormalities are typical features of the metabolic syndrome and may be associated to a pro-inflammatory gradient which in part may originate in the adipose tissue itself and directly affect the endothelium. An important link between obesity, the metabolic syndrome and dyslipidemia, seems to be the development of insulin resistance in peripheral tissues leading to an enhanced hepatic flux of fatty acids from dietary sources, intravascular lipolysis and from adipose tissue resistant to the antilipolytic effects of insulin. The current review will focus on these aspects of lipid metabolism in obesity and potential interventions to treat the obesity related dyslipidemia.
Overview
CoChat Summary
TL;DR
This narrative review describes how obesity-related insulin resistance, impaired triglyceride lipolysis, increased free fatty acid flux, and altered apolipoprotein/complement metabolism produce the characteristic dyslipidemia of high triglycerides, small dense LDL, and low HDL-C. It summarizes lifestyle and pharmacological approaches, emphasizing weight loss, statins, fibrates, niacin, omega-3 fatty acids, and apoB/non-HDL-C as treatment targets.
Key findings
- The hallmark of obesity dyslipidemia is elevated fasting and postprandial TG, small dense LDL, low HDL-C, and normal or slightly increased LDL-C, with increased apoB; hypertriglyceridemia may be the major cause of the other lipid abnormalities.
- Mechanisms include insulin resistance with enhanced hepatic FFA flux, hepatic overproduction of apoB-containing lipoproteins, reduced LPL mRNA in adipose tissue and LPL activity in skeletal muscle, elevated apo C-III, increased CETP-mediated lipid exchange, hepatic lipase action, and reduced LDL receptor expression; ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects versus lean controls.
- Atherogenic features include small dense LDL with a five-day residence time and chylomicron remnants that contain approximately 40 times more cholesterol per particle than LDL; postprandial hyperlipidemia with atherogenic remnants is especially linked to visceral obesity.
- Treatment findings include: weight loss of 4–10 kg reduced LDL-C by 12% and increased LDL receptor mRNA by 27%; moderate weight loss of approximately 10% reduced postprandial TG by 27%–46%; fibrates reduce TG by approximately 30%, LDL-C by 8%, and increase HDL-C by an average of 9%; niacin lowers TG by 15%–35% and raises HDL-C by 10%–25%; omega-3 fatty acids reduce plasma TG by 25%–30%; ezetimibe gives an additional 20% LDL-C lowering.
Methods
- Narrative review of lipid metabolism in obesity, including general lipoprotein metabolism, obesity-induced changes, FFA/inflammation interplay, lifestyle interventions, and pharmacological treatment.
- No primary data or study sample; the paper synthesizes published literature and cites prior studies, including metabolic ward studies, stable isotope studies, randomized trials, and meta-analyses.
- Main analysis is qualitative synthesis; no systematic search strategy, meta-analysis, or formal quality assessment is described.
Limitations
- The paper does not explicitly state limitations of the review itself. It notes evidence gaps, including that specific data on niacin plus statins in obesity remain scarce, that increasing HDL-C by exercise remains controversial, and that controversy exists about fibrate therapy on top of statin therapy.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal risk-of-bias assessment, and it reports no primary outcomes of its own.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
4 Valid · 0 Not valid · 28 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Visceral obesity leads to insulin resistance in part mediated by adipokines and free fatty acids (FFA).”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 1. Introduction
What the sources say
- Supportedcites [2] Flock, 2011, Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol, Adv. Nutr. source
The “Potential mechanisms altering lipid metabolism” section says excess adipose tissue leads to insulin resistance and identifies circulating adipokines and fatty acids as contributors. The “Weight reduction improves insulin sensitivity and LDL uptake” section specifically links abdominal adiposity with insulin resistance. Page numbers are not available in our copy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The amount of liberated FFA from chylomicrons and VLDL depends on the activity of LPL, which is stimulated by insulin [17,18].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
What the sources say
- Partly supportedcites [17] Karpe, 2011, Fatty acids, obesity, and insulin resistance: Time for a reevaluation, Diabetes sourceExperimental — accuracy not yet measured
Karpe et al. (2011) support the first half of the sentence: in FATTY ACIDS AND METABOLIC PHYSIOLOGY they state that 'Lipoprotein lipase (LPL) in the capillaries of adipose tissue hydrolyses circulating TG, mainly the dietary fat carried in the chylomicrons,' that VLDL-TG is likewise hydrolysed by LPL, and that 'the lower LPL activity leaves more TG unlipolysed in the triglyceride-rich lipoproteins' — i.e. the amount of fatty acid liberated depends on LPL activity. However, no passage of our copy (searched: LPL stimulated by insulin, insulin action on adipose LPL/activity, LPL activity determining fatty acid release) states that LPL activity is stimulated by insulin; the only acute LPL activation described is by heparin ('Heparin releases LPL from its endothelial binding sites and also activates the enzyme,' PATHOPHYSIOLOGY), and insulin's role in the paper is antilipolytic suppression of fat mobilization (METABOLIC PHYSIOLOGY). The insulin-stimulation clause attributed to this source is therefore not supported. (LLM, conf=0.75)
- Supportedcites [18] McQuaid, 2011, Downregulation of adipose tissue fatty acid trafficking in obesity: A driver for ectopic fat deposition?, Diabetes source
The Abstract (CONCLUSIONS) of our copy states in its own voice that 'In the postprandial period, insulin stimulates fat deposition into adipose tissue. This occurs by hydrolysis of chylomicron triglycerides (TGs) by lipoprotein lipase (LPL) bound to capillary endothelium', i.e. insulin drives the LPL-mediated liberation of fatty acids from TG-rich lipoproteins. The Discussion adds that LPL mediates lipolysis of both chylomicron and VLDL-TG and that postprandial upregulation of adipose tissue LPL occurs in lean but not obese subjects, consistent with insulin stimulation of LPL activity. This is background framing in the cited paper rather than its own experimental measurement, but our copy clearly treats the topic as stated. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, it has been described that ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects with or without insulin resistance when compared to lean controls [50].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 4. Interplay between FFA Metabolism and Inflammation in Obesity: Crossroad between Innate Immunity and Lipid Metabolism
What the sources say
- Partly supportedcites [50] Tinahones, 2011, Adipose tissue gene expression of factors related to lipid processing in obesity, PLoS One sourceExperimental — accuracy not yet measured
The Results state that visceral adipose tissue C3/ASP mRNA expression was higher in lean controls than in every obese group. But Table 2 shows reductions of about 44% in obese subjects and 49% in morbidly obese subjects with low insulin resistance, versus about 23% in the morbidly obese high-insulin-resistance/T2DM group. Thus, the approximately 40% reduction does not describe all the groups claimed. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“It is widely recognized that plasma FFA are elevated in obese people as a consequence of an increased fatty acid release from adipose tissue and a reduction in plasma FFA clearance [85,86,87].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 4. Interplay between FFA Metabolism and Inflammation in Obesity: Crossroad between Innate Immunity and Lipid Metabolism
What the sources say
- Not checked yetcites [85] Bjorntorp, 1969, Plasma free fatty acid turnover rate in obesity, Acta Med. Scand. source
- Not checked yetcites [86] Mook, 2004, In vivo regulation of plasma free fatty acids in insulin resistance, Metabolism source
- Not checked yetcites [87] Verseyden, 2004, Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3, Am. J. Clin. Nutr. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“The exchange of TG from these remnants for cholesterol-esters from HDL by CETP with the concerted action of hepatic lipase, ultimately leads to the formation of small dense LDL [48,49].”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
What the sources say
- Not checked yetcites [48] Capell, 1996, Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B, Arterioscler Thromb. Vasc. Biol. source
- Not checked yetcites [49] Hokanson, 1995, LDL physical and chemical properties in familial combined hyperlipidemia, Arterioscler. Thromb. Vasc. Biol. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
14 more claims
Create a free account to see all 38 claims and to verify the 51 references still open.
- It may state two separate claims as one. 18
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated leptin and cholesterol levels are characteristic of obesity, and therefore these results further demonstrate the extent of the obese phenotype observed in Abi3–/– mice (Klop et al., 2013; Obradovic et al., 2021).”
From Deletion of the Alzheimer’s disease risk gene Abi3 locus results in obesity and systemic metabolic disruption in mice (2022) · cites this paper as Klop et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is common for individuals afflicted with obesity to exhibit changes in the makeup of their circulating plasma fats, a condition known as dyslipidemia. This typically includes elevated levels of apolipoprotein B (apoB), diminished levels of high-density lipoprotein, and alterations in low-density lipoprotein’s particle composition (LDL).”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [51]
In the citing paper
“Obesity has a clear correlation with the incidence of cardiovascular disorders including hypertension, coronary artery disease, heart failure and sudden death”
In the citing paper
“many patients with insulin resistance, the main etiology of T2DM, tend to have high triglyceride and low HDL levels [53,54,55]”
In the citing paper
“Chronically elevated serum cholesterol, particularly LDL, contribute to the degenerative accumulation of plaques in the arteries, which can lead to progressive narrowing or blocking of blood vessels (Klop et al., 2013).”
From Population genomics reveal recent speciation and rapid evolutionary adaptation in polar bears (2014) · cites this paper as Klop et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
“the increased TG content within the LDL is hydrolyzed by hepatic lipase, which leads to the formation of small, dense LDL particles.”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 3. Obesity Induced Changes in Lipoprotein Metabolism and Atherogenic Effects
“Hypertriglyceridemia further induces an increased exchange of cholesterolesters (CE) and TG between VLDL and HDL and low density lipoproteins (LDL) by cholesterylester-transfer-protein (CETP). This leads to decreased HDL-C concentrations and a reduction in TG content in LDL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
“Within the circulation, the HDL particles also become enriched with cholesterol-esters by the action of cholesterylester-transfer-protein (CETP) and phospholipid transfer protein (PLTP).”
§ Dyslipidemia in Obesity: Mechanisms and Potential Targets > 2. Overview of Lipoprotein Metabolism
“In this process HDL acquires TG from TG-rich lipoproteins in exchange for cholesterol-esters as a direct consequence of the CETP action [11].”
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“However, there is controversy about the effectiveness of fibrate therapy on top of statin therapy since the ACCORD trial was unable to confirm a beneficial effect on cardiovascular endpoints by fenofibrate combined with statins in diabetic patients [156].”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“All these mechanisms have been related to the higher incidence of cardiovascular disease seen in obesity [82].”
BackgroundWaist circumference as a measure for indicating need for weight management
Lean, M. E. J., Han, T. S., & Morrison, C. E. (1995) · BMJ · doi:10.1136/bmj.311.6998.158 · Cited by 1,869 · cited 1×
“It has been shown that diurnal triglyceridemia in obese subjects correlates better to waist circumference than to body mass index [78,80], which is in agreement with the hypothesis that the distribution of adipose tissue modulates postprandial lipemia [81].”
ResultNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Goldstein, J. L., & Brown, M. S. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179564 · Cited by 1,344 · cited 1×
“In contrast, LDL is primarily taken up by the liver via the LDL receptor [31,32].”
BackgroundRelation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Fatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896 · cited 2×
“insulin resistance as seen in obesity [17].”
BackgroundEvaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · cited 2×
“treatment targets next to LDL-C levels in the presence of the hypertriglyceridemic waist [11,136,138].”
BackgroundObesity, insulin resistance and free fatty acids
Boden, G. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283444b09 · Cited by 848 · cited 2×
“Other reviews have been published recently by several other groups as well [3,84].”
BackgroundA Trial of Sugar-free or Sugar-Sweetened Beverages and Body Weight in Children
de Ruyter, J. C., Olthof, M. R., Seidell, J. C., & Katan, M. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203034 · Cited by 814 · cited 1×
“This has already been demonstrated in early childhood [110].”
BackgroundEffect of a single high-fat meal on endothelial function in healthy subjects
Vogel, R. A., Corretti, M. C., & Plotnick, G. D. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00760-6 · Cited by 798 · cited 1×
“In addition to a direct detrimental effect by chylomicron remnants on vessels [59], impaired endothelial function after an oral fat load [70] and after infusion of artificial TG-rich lipoproteins have been described [71].”
BackgroundBoekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795 · cited 1×
“Although others did not describe any benefit of apo B or non-HDL-C over LDL-C levels to assess cardiovascular risk [140–142].”
BackgroundElevated circulating free fatty acid levels impair endothelium-dependent vasodilation
Steinberg, H. O., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B., & Baron, A. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119636 · Cited by 761 · cited 1×
“This phenomenon may take place by elevated levels of FFA [72], which are generated by the action of LPL mediated lipolysis.”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659 · cited 1×
“apo B as treatment target over LDL-C would prevent an additional 300,000–500,000 cardiovascular events in the US population over a 10-year period [139].”
BackgroundDavis, H. R., Zhu, L.-J., Hoos, L. M., Tetzloff, G., Maguire, M., Liu, J., Yao, X., Iyer, S. P. N., Lam, M.-H., Lund, E. G., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405817200 · Cited by 615 · cited 3×
“Cholesterol is taken up by the enterocytes via the specific cholesterol transporter Niemann-Pick C1 Like 1 protein (NPC1L1) [9,10].”
Kowal, R. C., Herz, J., Goldstein, J. L., Esser, V, & Brown, M. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5810 · Cited by 595 · cited 1×
“protein and heparan sulphate proteoglycans [25–30].”
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · cited 1×
“20 mmol/L [151–155].”
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.
Groot, P. H., van Stiphout, W. A., Krauss, X. H., Jansen, H., van Tol, A., van Ramshorst, E., Chin-On, S., Hofman, A., Cresswell, S. R., & Havekes, L. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.3.653 · Cited by 530 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundRaal, F., Scott, R., Somaratne, R., Bridges, I., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 508 · cited 3×
“process of the LDL receptor, which is regulated by the proprotein convertase subtilisin/kexin type 9 (PCSK9) [32,33].”
BackgroundJørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501 · cited 1×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundBrunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484 · cited 15×
“This phenomenon may take place by elevated levels of FFA [72], which are generated by the action of LPL mediated lipolysis.”
BackgroundInfluentialPostprandial lipoproteins and progression of coronary atherosclerosis
Karpe, F., Steiner, G., Uffelman, K., Olivecrona, T., & Hamsten, A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90085-x · Cited by 483 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundBeisiegel, U., Weber, W., & Bengtsson-Olivecrona, G. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8342 · Cited by 468 · cited 1×
“protein and heparan sulphate proteoglycans [25–30].”
Lambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Mahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Downregulation of Adipose Tissue Fatty Acid Trafficking in Obesity
McQuaid, S. E., Hodson, L., Neville, M. J., Dennis, A. L., Cheeseman, J., Humphreys, S. M., Ruge, T., Gilbert, M., Fielding, B. A., Frayn, K. N., et al. (2011) · Diabetes · doi:10.2337/db10-0867 · Cited by 366
Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways
Goldberg, I. J., Eckel, R. H., & Abumrad, N. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800085-jlr200 · Cited by 362
Role of the Gut in Lipid Homeostasis
Abumrad, N. A., & Davidson, N. O. (2012) · Physiological Reviews · doi:10.1152/physrev.00019.2011 · Cited by 355 · cited 2×
“Subsequently, the cholesterol within HDL becomes esterified into cholesterol-esters by HDL associated lecithin-cholesterol acyltransferase (LCAT) [23].”
BackgroundGPIHBP1 Is Responsible for the Entry of Lipoprotein Lipase into Capillaries
Davies, B. S. J., Beigneux, A. P., Barnes, R. H., Tu, Y., Gin, P., Weinstein, M. M., Nobumori, C., Nyrén, R., Goldberg, I., Olivecrona, G., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.04.016 · Cited by 342 · cited 1×
“LPL serves as the docking station for chylomicrons and VLDL for adherence to the endothelium via glycosyl-phosphatidylinositol-anchored high-density-binding protein 1 (GPIHBP1), which is present on the luminal side of the endothelium [14–16].”
BackgroundFrom excess adiposity to insulin resistance: The role of free fatty acids
Capurso, C., & Capurso, A. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.05.003 · Cited by 337 · cited 1×
“The increase in FFA and obesity-induced inflammation play a crucial role in the development of insulin resistance [88].”
BackgroundTchernof, A., Lamarche, B., Prud'homme, D., Nadeau, A., Moorjani, S., Labrie, F., Lupien, P. J., & Després, J.-P. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.629 · Cited by 323 · cited 1×
“The development of small dense LDL in obesity is mainly due to increased TG concentrations and does not depend on total body fat mass [53].”
BackgroundDietary, physiological, genetic and pathological influences on postprandial lipid metabolism
Lopez-Miranda, J., Williams, C., & Lairon, D. (2007) · British Journal of Nutrition · doi:10.1017/s000711450774268x · Cited by 320 · cited 2×
“The type of dietary fat also affects postprandial lipemia [109].”
BackgroundTenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 311 · cited 1×
“20 mmol/L [151–155].”
Sullivan, S., Kirk, E. P., Mittendorfer, B., Patterson, B. W., & Klein, S. (2012) · Hepatology · doi:10.1002/hep.25548 · Cited by 301 · cited 1×
“for 16 weeks in obese subjects with NAFLD resulted in a small reduction in intra-hepatic TG content, although no changes in VLDL-TG or apoB100 secretion were observed [127].”
BackgroundApolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · cited 1×
“Plasma apo C-III concentrations correlate positively with plasma TG [19].”
BackgroundPostprandial triglyceride response in visceral obesity in men
Couillard, C., Bergeron, N., Prud'homme, D., Bergeron, J., Tremblay, A., Bouchard, C., Mauriège, P., & Després, J. P. (1998) · Diabetes · doi:10.2337/diabetes.47.6.953 · Cited by 271 · cited 1×
“Postprandial hyperlipidemia with accumulation of atherogenic remnants is especially linked to visceral obesity [75,76].”
BackgroundFranssen, R., Monajemi, H., Stroes, E. S. G., & Kastelein, J. J. P. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.003 · Cited by 270
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268 · cited 2×
“diagnostic tests are warranted to test for the presence of familial hypertriglyceridemia or familial dysbetalipoproteinemia [11,136,138,144].”
Effects of four different single exercise sessions on lipids, lipoproteins, and lipoprotein lipase
Ferguson, M. A., Alderson, N. L., Trost, S. G., Essig, D. A., Burke, J. R., & Durstine, J. L. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.3.1169 · Cited by 245 · cited 1×
“Physical exercise has been shown to increase LPL and hepatic lipase activity, which stimulates TG lipolysis [123,124].”
BackgroundFatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport
Peterson, J., Bihain, B. E., Bengtsson-Olivecrona, G., Deckelbaum, R. J., Carpentier, Y. A., & Olivecrona, T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.3.909 · Cited by 237 · cited 1×
“Increased postprandial lipemia leads to elevated levels of FFA, resulting in detachment of LPL from its endothelial surface [51,52].”
BackgroundLundman, P., Eriksson, M., Schenck-Gustafsson, K., Karpe, F., & Tornvall, P. (1997) · Circulation · doi:10.1161/01.cir.96.10.3266 · Cited by 234 · cited 1×
“In addition to a direct detrimental effect by chylomicron remnants on vessels [59], impaired endothelial function after an oral fat load [70] and after infusion of artificial TG-rich lipoproteins have been described [71].”
BackgroundImpact of obesity on cardiovascular disease
Zalesin, K. C., Franklin, B. A., Miller, W. M., Peterson, E. D., & McCullough, P. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.005 · Cited by 231 · cited 1×
“Obesity, especially central obesity, is probably the main cause of the metabolic syndrome (MetS), which includes insulin resistance, type 2 diabetes mellitus, hypertension, the obstructive sleep apnea syndrome, non-alcoholic fatty liver disease (NAFLD) and dyslipidemia, all risk factors for cardiovascular disease [3,4…”
BackgroundTriacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein
Packard, C. J. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311066 · Cited by 225 · cited 1×
“Small dense LDL are relatively slowly metabolized with a five day residence time, which enhances its atherogenicity [54].”
BackgroundResistant Starch from High-Amylose Maize Increases Insulin Sensitivity in Overweight and Obese Men
Maki, K. C., Pelkman, C. L., Finocchiaro, E. T., Kelley, K. M., Lawless, A. L., Schild, A. L., & Rains, T. M. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.152975 · Cited by 221 · cited 2×
“However, no effect from resistant starch supplementation was observed on TG and cholesterol concentrations [132,133].”
BackgroundBaldo, A., Sniderman, A. D., St-Luce, S., Avramoglu, R. K., Maslowska, M., Hoang, B., Monge, J. C., Bell, A., Mulay, S., & Cianflone, K. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116733 · Cited by 221 · cited 1×
“intracellular esterification into TG [21,22].”
The role of dietary fatty acids in the pathology of metabolic syndrome
Lottenberg, A. M., Afonso, M. D. S., Lavrador, M. S. F., Machado, R. M., & Nakandakare, E. R. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.03.004 · Cited by 220 · cited 2×
“concerning PUFA and inflammation is not consistent [89,90].”
BackgroundHussain, M. M., Maxfield, F. R., Más-Oliva, J., Tabas, I., Ji, Z. S., Innerarity, T. L., & Mahley, R. W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92792-4 · Cited by 211 · cited 1×
“protein and heparan sulphate proteoglycans [25–30].”
Maio, A., & Dowd, F. J. (2010) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60628-2 · Cited by 209
Basic carboxypeptidases: regulators of peptide hormone activity
Skidgel, R. A. (1988) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(88)90015-6 · Cited by 208 · cited 1×
“By the action of factor B and factor D (also secreted by adipocytes and fibroblasts) a small active fragment is split (C3a) from C3, which is readily converted into C3adesArg (also known as ASP) by carboxypeptidase N (Figure 2) [97].”
BackgroundChylomicrons and chylomicron remnants in coronary artery disease: a case-control study
Simons, L. A., Dwyer, T., Simons, J., Bernstein, L., Mock, P., Pooma, N. S., Balasubramaniam, S., Baron, D., Branson, J., Morgan, J., et al. (1987) · Atherosclerosis · doi:10.1016/0021-9150(87)90020-7 · Cited by 205 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundKristiansson, K., Perola, M., Tikkanen, E., Kettunen, J., Surakka, I., Havulinna, A. S., Stančáková, A., Barnes, C., Widen, E., Kajantie, E., et al. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.961482 · Cited by 204
Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis
Proctor, S. D., Vine, D. F., & Mamo, J. C. L. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200210000-00001 · Cited by 201
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 200 · cited 1×
“to less free cholesterol and anti-oxidative content [60].”
BackgroundCastro Cabezas, M., de Bruin, T. W., de Valk, H. W., Shoulders, C. C., Jansen, H., & Willem Erkelens, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116544 · Cited by 200 · cited 1×
“the major cause of the other lipid abnormalities since it will lead to delayed clearance of the TG-rich lipoproteins [34–48] and formation of small dense LDL [48,49].”
BackgroundSelf-citationHepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender and diet.
Deeb, S. S., Zambon, A., Carr, M. C., Ayyobi, A. F., & Brunzell, J. D. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200017-jlr200 · Cited by 193 · cited 1×
“This will ultimately lead to lower levels of HDL-C and a reduction in circulating HDL particles with impairment of reversed cholesterol transport [83].”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.012 · Cited by 192
Tenkanen, L., Mänttäri, M., & Manninen, V. (1995) · Circulation · doi:10.1161/01.cir.92.7.1779 · Cited by 188
Pacifico, L., Anania, C., Osborn, J. F., Ferraro, F., Bonci, E., Olivero, E., & Chiesa, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0545 · Cited by 182 · cited 1×
“This process takes place at the liver and acts as an anti-atherogenic mechanism, but it may also take place in other tissues where cholesterol can not be removed efficiently leading to cholesterol accumulation and therefore the initiation of the atherosclerotic plaque [56,57,61,62].”
BackgroundThe metabolism of triglyceride-rich lipoproteins revisited: New players, new insight
Dallinga-Thie, G. M., Franssen, R., Mooij, H. L., Visser, M. E., Hassing, H. C., Peelman, F., Kastelein, J. J. P., Péterfy, M., & Nieuwdorp, M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.027 · Cited by 181 · cited 1×
“LPL serves as the docking station for chylomicrons and VLDL for adherence to the endothelium via glycosyl-phosphatidylinositol-anchored high-density-binding protein 1 (GPIHBP1), which is present on the luminal side of the endothelium [14–16].”
BackgroundCorella, D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.343 · Cited by 170 · cited 2×
“47) [120].”
BackgroundPostprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects
Ryu, J. E., Howard, G., Craven, T. E., Bond, M. G., Hagaman, A. P., & Crouse, J. R. (1992) · Stroke · doi:10.1161/01.str.23.6.823 · Cited by 169 · cited 1×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundThiazolidinediones and Blood Lipids in Type 2 Diabetes
van Wijk, J. P. H., de Koning, E. J. P., Martens, E. P., & Rabelink, T. J. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000090521.25968.4d · Cited by 165 · cited 2×
“In the case of thiazolidinedione derivatives, their mode of action causes an increase of body weight, due to expansion of the subcutaneous fat compartment, which makes these drugs less appropriate in the case of obesity [160].”
BackgroundCaron, S., Verrijken, A., Mertens, I., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 162 · cited 1×
“Elevated levels of apo C-III in obesity can be explained by glucose-stimulated transcription of apo C-III and it has been described that plasma apo C-III levels correlate with fasting glucose and glucose excursion after an oral glucose test in obese humans [65].”
BackgroundPlasma free fatty acid turnover rate in obesity
Björntorp, P., Bergman, H., & Varnauskas, E. (1969) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1969.tb07347.x · Cited by 161 · cited 1×
“It is widely recognized that plasma FFA are elevated in obese people as a consequence of an increased fatty acid release from adipose tissue and a reduction in plasma FFA clearance [85–87].”
BackgroundRegulation of Dietary Fatty Acid Entrapment in Subcutaneous Adipose Tissue and Skeletal Muscle
Evans, K., Burdge, G. C., Wootton, S. A., Clark, M. L., & Frayn, K. N. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2684 · Cited by 161 · cited 1×
“Despite the uptake of FFA by adipocytes and myocytes, a proportion of FFA remains in the plasma compartment (“spill over”) where the FFA are bound by albumin and transported to the liver [24].”
BackgroundChan, D. C., Watts, G. F., Barrett, P. H. R., Beilin, L. J., Redgrave, T. G., & Mori, T. A. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2377 · Cited by 160 · cited 3×
“Apo B represents the total number of atherogenic particles (chylomicrons, chylomicron remnants, VLDL, IDL and LDL), whereas non-HDL-C represents the amount of cholesterol in both the TG-rich lipoproteins and LDL. Recently, a meta-analysis has shown that implementation of non-HDL-C or apo B as treatment target over LDL…”
BackgroundDiseases and disorders associated with excess body weight.
Knight, J. A. (2011) · PubMed · Cited by 158
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects
Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153 · cited 1×
“co-workers showed that the defective clearance of remnant lipoproteins can be explained by elevated concentrations of apo C-III in the situation of obesity [64].”
BackgroundSaleh, J., Summers, L. K. M., Cianflone, K., Fielding, B. A., Sniderman, A. D., & Frayn, K. N. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32574-8 · Cited by 147
Germinario, R. J., Sniderman, A. D., Manuel, S., Lefebvre, S. P., Baldo, A., & Cianflone, K. (1993) · Metabolism · doi:10.1016/0026-0495(93)90215-a · Cited by 141 · cited 1×
“intracellular esterification into TG [21,22].”
New insights into the mechanism of low high-density lipoprotein cholesterol in obesity
Wang, H., & Peng, D.-Q. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-176 · Cited by 140 · cited 1×
“The concentrations of plasma apolipoprotein (apo) B are also often increased, partly due to the hepatic overproduction of apo B containing lipoproteins [6,7].”
BackgroundRobinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137 · cited 1×
“Although others did not describe any benefit of apo B or non-HDL-C over LDL-C levels to assess cardiovascular risk [140–142].”
BackgroundGinsberg, H. N., Jones, J., Blaner, W. S., Thomas, A., Karmally, W., Fields, L., Blood, D., & Begg, M. D. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.11.1829 · Cited by 129 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundTenkanen, L., Mänttäri, M., Kovanen, P. T., Virkkunen, H., & Manninen, V. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.743 · Cited by 129 · cited 1×
“20 mmol/L [151–155].”
Robertson, M. D., Wright, J. W., Loizon, E., Debard, C., Vidal, H., Shojaee-Moradie, F., Russell-Jones, D., & Umpleby, A. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1513 · Cited by 126 · cited 2×
“However, no effect from resistant starch supplementation was observed on TG and cholesterol concentrations [132,133].”
BackgroundImpaired chylomicron remnant clearance in familial combined hyperlipidemia.
Cabezas, M. C., de Bruin, T. W., Jansen, H., Kock, L. A., Kortlandt, W., & Erkelens, D. W. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.6.804 · Cited by 125 · cited 1×
“the major cause of the other lipid abnormalities since it will lead to delayed clearance of the TG-rich lipoproteins [34–48] and formation of small dense LDL [48,49].”
BackgroundSelf-citationProctor, S. D., & Mamo, J. C. L. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000084638.14534.0a · Cited by 125
Adipose tissue gene expression of factors related to lipid processing in obesity
Clemente-Postigo, M., Queipo-Ortuño, M. I., Fernandez-Garcia, D., Gomez-Huelgas, R., Tinahones, F. J., & Cardona, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024783 · Cited by 124 · cited 2×
“Recently, it has been described that ASP mRNA expression in visceral adipose tissue is reduced by approximately 40% in obese and morbidly obese subjects with or without insulin resistance when compared to lean controls [50].”
Backgroundvan Herpen, N. A., Schrauwen-Hinderling, V. B., Schaart, G., Mensink, R. P., & Schrauwen, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2243 · Cited by 124
Meyer, E., Westerveld, H. T., de Ruyter-Meijstek, F. C., van Greevenbroek, M. M. J., Rienks, R., van Rijn, H. J. M., Erkelens, D. W., & de Bruin, T. W. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05832-7 · Cited by 122 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundASP stimulates glucose transport in cultured human adipocytes
Maslowska, M., Sniderman, A. D., Germinario, R. J., & Cianflone, K. (1997) · International Journal of Obesity · doi:10.1038/sj.ijo.0800396 · Cited by 120 · cited 1×
“In addition, C3adesArg mediates insulin-independent trans-membrane glucose transport [98].”
BackgroundAcute in vitro production of acylation stimulating protein in differentiated human adipocytes.
Maslowska, M., Scantlebury, T., Germinario, R. J., & Cianflone, K. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37270-9 · Cited by 119
Lipoprotein lipase in plasma after an oral fat load: Relation to free fatty acids
Karpe, F., Olivecrona, T., Walldius, G., & Hamsten, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41413-0 · Cited by 118
Lai, C.-Q., Corella, D., Demissie, S., Cupples, L. A., Adiconis, X., Zhu, Y., Parnell, L. D., Tucker, K. L., & Ordovas, J. M. (2006) · Circulation · doi:10.1161/circulationaha.105.577296 · Cited by 117 · cited 2×
“population [121].”
BackgroundMarkers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity
Chan, D. C., Watts, G. F., Barrett, P. H., Mamo, J. C., & Redgrave, T. G. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.278 · Cited by 117 · cited 1×
“and non-fasting TG concentrations, which can be attributed to an increase in LPL activity with a concomitant reduction in apo C-III levels [111], a decrease in CETP activity [112,113] and an increased catabolism of TG-rich lipoproteins [114].”
BackgroundNovel aspects of postprandial lipemia in relation to atherosclerosis
Alipour, A., Elte, J. W. F., van Zaanen, H. C. T., Rietveld, A. P., & Cabezas, M. C. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.007 · Cited by 113 · cited 1×
“Other mechanisms of remnant-mediated atherogenesis which may play a role in obesity comprise the postprandial activation of leukocytes, generation of oxidative stress and production of cytokines [55,73,74].”
BackgroundSelf-citationMamo, J. C. L., Watts, G. F., Barrett, P. H. R., Smith, D., James, A. P., & Pal, S. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.3.e626 · Cited by 112 · cited 1×
“Finally, the LDL receptor expression is reduced in obesity [66].”
BackgroundHalkes, C. J. M., van Dijk, H., de Jaegere, P. P. T., Plokker, H. W. M., van der Helm, Y., Erkelens, D. W., & Castro Cabezas, M. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0901.095276 · Cited by 112
Self-citationThe new joint EAS/ESC guidelines for the management of dyslipidaemias
Catapano, A. L., Chapman, J., Wiklund, O., & Taskinen, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.011 · Cited by 111
Inhibition of hepatic lipase activity impairs chylomicron remnant-removal in rats
Sultan, F., Lagrange, D., Jansen, H., & Griglio, S. (1990) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(90)90071-5 · Cited by 110 · cited 1×
“protein and heparan sulphate proteoglycans [25–30].”
Pan, X., & Hussain, M. M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.013 · Cited by 109 · cited 5×
“ingestion of a meal containing fat, TG are lipolyzed in the intestinal lumen into FFA and 2-monoacylglycerols (MAG) and are taken up by the enterocytes via passive diffusion and specific transporters like CD36 [8].”
BackgroundInfluentialMora, S., Glynn, R. J., Boekholdt, S. M., Nordestgaard, B. G., Kastelein, J. J. P., & Ridker, P. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.035 · Cited by 108
Klop, B., Proctor, S. D., Mamo, J. C. L., Botham, K. M., & Cabezas, M. C. (2011) · International Journal of Vascular Medicine · doi:10.1155/2012/947417 · Cited by 108 · cited 1×
“Other mechanisms of remnant-mediated atherogenesis which may play a role in obesity comprise the postprandial activation of leukocytes, generation of oxidative stress and production of cytokines [55,73,74].”
BackgroundSelf-citationClinical Assessment and Management of Adult Obesity
Kushner, R. F. (2012) · Circulation · doi:10.1161/circulationaha.111.075424 · Cited by 106
Proctor, S. D., Vine, D. F., & Mamo, J. C. L. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000143859.75035.5a · Cited by 103 · cited 1×
“This process takes place at the liver and acts as an anti-atherogenic mechanism, but it may also take place in other tissues where cholesterol can not be removed efficiently leading to cholesterol accumulation and therefore the initiation of the atherosclerotic plaque [56,57,61,62].”
Backgroundvan Oostrom, A. J. H. H. M., Alipour, A., Plokker, T. W. M., Sniderman, A. D., & Cabezas, M. C. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.01.009 · Cited by 102 · cited 1×
“Our group and others were able to demonstrate that the complement component 3 (C3) is one of the major determinants of the MetS [99–101] and postprandial lipemia in insulin resistant subjects, but also in insulin sensitive subjects [87,102,103].”
ResultSelf-citationWatts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
Capell, W. H., Zambon, A., Austin, M. A., Brunzell, J. D., & Hokanson, J. E. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.8.1040 · Cited by 95 · cited 2×
“the major cause of the other lipid abnormalities since it will lead to delayed clearance of the TG-rich lipoproteins [34–48] and formation of small dense LDL [48,49].”
BackgroundCruz‐Teno, C., Pérez‐Martínez, P., Delgado‐Lista, J., Yubero‐Serrano, E. M., García‐Ríos, A., Marín, C., Gómez, P., Jiménez‐Gómez, Y., Camargo, A., Rodríguez-Cantalejo, F., et al. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200096 · Cited by 87 · cited 7×
“Our group and others were able to demonstrate that the complement component 3 (C3) is one of the major determinants of the MetS [99–101] and postprandial lipemia in insulin resistant subjects, but also in insulin sensitive subjects [87,102,103].”
BackgroundInfluentialDifferentiation‐induced production of ASP in human adipocytes
Cianflone, K., & Maslowska, M. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01690.x · Cited by 86 · cited 1×
“In reaction to fatty acid delivery, adipocytes and fibroblasts secrete complement component 3 (C3) [93–96].”
BackgroundSentí, M., Nogués, X., Pedro-Botet, J., Rubiés-Prat, J., & Vidal-Barraquer, F. (1992) · Circulation · doi:10.1161/01.cir.85.1.30 · Cited by 85 · cited 1×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundZhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039062 · Cited by 84 · cited 2×
“13 mmol/L reduction in TG, whereas rimonabant did not show any lipid improvements [134].”
BackgroundAron-Wisnewsky, J., Julia, Z., Poitou, C., Bouillot, J.-L., Basdevant, A., Chapman, M. J., Clement, K., & Guerin, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2378 · Cited by 84
Diurnal triglyceride profiles: a novel approach to study triglyceride changes
Cabezas, M. C., Halkes, C. J. M., Meijssen, S., van Oostrom, A. J. H. H. M., & Erkelens, D. W. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00554-2 · Cited by 84 · cited 2×
“A more physiological method to study postprandial lipemia has been developed in our laboratory, namely the measurement of daytime capillary TG profiles using repeated capillary self-measurements in an out of hospital situation [78,79].”
MethodResultSelf-citationHyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load.
Genest, J., Sniderman, A., Cianflone, K., Teng, B., Wacholder, S., Marcel, Y., & Kwiterovich, P. (1986) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.6.3.297 · Cited by 83
Flock, M. R., Green, M. H., & Kris-Etherton, P. M. (2011) · Advances in Nutrition · doi:10.3945/an.111.000422 · Cited by 82 · cited 1×
“In addition, cytokines like TNF-α and IL-6, which originate from macrophages in adipose tissue, are involved [2].”
Backgroundvan Oostrom, A. J. H. H. M., van Wijk, J. P. H., & Cabezas, M. C. (2004) · Drugs · doi:10.2165/00003495-200464002-00004 · Cited by 77
Self-citationLDL physical and chemical properties in familial combined hyperlipidemia
Hokanson, J. E., Krauss, R. M., Albers, J. J., Austin, M. A., & Brunzell, J. D. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.452 · Cited by 76 · cited 2×
“the major cause of the other lipid abnormalities since it will lead to delayed clearance of the TG-rich lipoproteins [34–48] and formation of small dense LDL [48,49].”
BackgroundSánchez-Moreno, C., Ordovás, J. M., Smith, C. E., Baraza, J. C., Lee, Y., & Garaulet, M. (2011) · Journal of Nutrition · doi:10.3945/jn.110.130344 · Cited by 75 · cited 1×
“associated with increased plasma TG, appear to be more resistant to weight gain by fat consumption and showed an inverse relationship between fat intake and plasma TG [122].”
BackgroundSears, B., & Ricordi, C. (2012) · PubMed · Cited by 75
Cabezas, M. C., de Bruin, T. W., Kock, L. A., Kortlandt, W., Trip, M. V. L.-S., Jansen, H., & Erkelens, D. W. (1993) · Metabolism · doi:10.1016/0026-0495(93)90109-2 · Cited by 74 · cited 1×
“the major cause of the other lipid abnormalities since it will lead to delayed clearance of the TG-rich lipoproteins [34–48] and formation of small dense LDL [48,49].”
BackgroundSelf-citationRoberts, C. K., Barnard, R. J., Liang, K. H., & Vaziri, N. D. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00622-0 · Cited by 70 · cited 1×
“A study in rats showed that a diet high in saturated fats reduced LPL protein levels and LPL activity in skeletal muscle, whereas LPL activity was increased in adipose tissue favoring shunting of lipids from skeletal muscle to adipose tissue [116].”
BackgroundChan, D. C., & Watts, G. F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.502529 · Cited by 69 · cited 4×
“VLDL synthesis, a slight increase in HDL production rate and decreased catabolism of HDL [146].”
BackgroundInfluentialObesity and diabetes: lipids, ‘nowhere to run to'
Hill, M. J., Metcalfe, D., & McTernan, P. G. (2009) · Clinical Science · doi:10.1042/cs20080050 · Cited by 68 · cited 1×
“Other reviews have been published recently by several other groups as well [3,84].”
BackgroundGender differences in diurnal triglyceridemia in lean and overweight subjects
Halkes, C. J. M., Cabezas, M. C., van Wijk, J., & Erkelens, D. W. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801831 · Cited by 64 · cited 1×
“It has been shown that diurnal triglyceridemia in obese subjects correlates better to waist circumference than to body mass index [78,80], which is in agreement with the hypothesis that the distribution of adipose tissue modulates postprandial lipemia [81].”
ResultSelf-citationvan Oostrom, A. J. H. H. M., Cabezas, M. C., Ribalta, J., Masana, L., Twickler, T. B., Remijnse, T. A. W., & Erkelens, D. W. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00732.x · Cited by 63 · cited 1×
“A more physiological method to study postprandial lipemia has been developed in our laboratory, namely the measurement of daytime capillary TG profiles using repeated capillary self-measurements in an out of hospital situation [78,79].”
MethodSelf-citationSakata, K., Miho, N., Shirotani, M., Yoshida, H., Takada, Y., & Takada, A. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00209-8 · Cited by 62 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundSeveral genetic polymorphisms interact with overweight/obesity to influence serum lipid levels
Yin, R.-X., Wu, D.-F., Miao, L., Aung, L. H., Cao, X.-L., Yan, T.-T., Long, X.-J., Liu, W.-Y., Zhang, L., & Li, M. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-123 · Cited by 62
Of mice and men (and women) and the acylation-stimulating protein pathway
Sniderman, A. D., Maslowska, M., & Cianflone, K. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200006000-00010 · Cited by 60 · cited 1×
“ASP in relation to peripheral fatty acid trapping was first described by Sniderman and collaborators [92].”
BackgroundNew wrinkles in lipoprotein lipase biology
Davies, B. S. J., Beigneux, A. P., Fong, L. G., & Young, S. G. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834d0b33 · Cited by 59 · cited 1×
“LPL serves as the docking station for chylomicrons and VLDL for adherence to the endothelium via glycosyl-phosphatidylinositol-anchored high-density-binding protein 1 (GPIHBP1), which is present on the luminal side of the endothelium [14–16].”
BackgroundIn vivo regulation of plasma free fatty acids in insulin resistance
Mook, S., Halkes, C. J. M., Bilecen, S., & Cabezas, M. C. (2004) · Metabolism · doi:10.1016/j.metabol.2004.02.023 · Cited by 59 · cited 1×
“It is widely recognized that plasma FFA are elevated in obese people as a consequence of an increased fatty acid release from adipose tissue and a reduction in plasma FFA clearance [85–87].”
BackgroundSelf-citationMeijssen, S., van Dijk, H., Verseyden, C., Erkelens, D. W., & Cabezas, M. C. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000014079.98335.72 · Cited by 57 · cited 2×
“ASP/C3adesArg resistance plays a role in adequate peripheral fatty acid handling [102,106,107].”
BackgroundResultSelf-citationDrug Treatment of Hyperlipidaemia: A Guide to the Rational Use of Lipid-Lowering Drugs
Toth, P. P. (2010) · Drugs · doi:10.2165/10898610-000000000-00000 · Cited by 57
James, A. P., Watts, G. F., Barrett, P. H. R., Smith, D., Pal, S., Chan, D. C., & Mamo, J. C. L. (2003) · Metabolism · doi:10.1053/meta.2003.50032 · Cited by 54 · cited 1×
“A weight loss of 4–10 kg in obese subjects resulted in a 12% reduction in LDL-C and a 27% increase in LDL receptor mRNA levels [111,115].”
BackgroundDoes Exercise Increase HDL Cholesterol in Those Who Need It the Most?
Thompson, P. D., & Rader, D. J. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.092147 · Cited by 54 · cited 1×
“The plasma TG lowering effect of exercise and weight loss is the most consistent finding in studies concerning blood lipids [130], whereas increasing HDL-C levels by exercise remains controversial, especially in those subjects with high TG and low HDL-C levels [131].”
BackgroundMetabolic response of Acylation Stimulating Protein to an oral fat load.
Cianflone, K., Vu, H., Walsh, M., Baldo, A., & Sniderman, A. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38229-8 · Cited by 53
van Oostrom, A. J., van Dijk, H., Verseyden, C., Sniderman, A. D., Cianflone, K., Rabelink, T. J., & Castro Cabezas, M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.3.510 · Cited by 53 · cited 1×
“Our group and others were able to demonstrate that the complement component 3 (C3) is one of the major determinants of the MetS [99–101] and postprandial lipemia in insulin resistant subjects, but also in insulin sensitive subjects [87,102,103].”
ResultMeijssen, S., Cabezas, M. C., Twickler, T. B., Jansen, H., & Erkelens, D. W. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32015-0 · Cited by 53
Self-citationPatalay, M., Lofgren, I. E., Freake, H. C., Koo, S. I., & Fernandez, M. L. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.4.735 · Cited by 53 · cited 2×
“A weight loss of 4–10 kg in obese subjects resulted in a 12% reduction in LDL-C and a 27% increase in LDL receptor mRNA levels [111,115].”
BackgroundHarrison, M., Moyna, N. M., Zderic, T. W., O’Gorman, D. J., McCaffrey, N., Carson, B. P., & Hamilton, M. T. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-64 · Cited by 52 · cited 1×
“confirmed in a recent study [125].”
Exercise and fat accumulation in the human liver
Magkos, F. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833ea912 · Cited by 50 · cited 1×
“Exercise induced reductions in intra-hepatic TG content have also been reported even in the absence of weight loss [128].”
BackgroundEffect of exercise and medium-chain fatty acids on postprandial lipemia
Thomas, T. R., Horner, K. E., Langdon, M. M., Zhang, J. Q., Krul, E. S., Sun, G. Y., & Cox, R. H. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.90.4.1239 · Cited by 48 · cited 1×
“Physical exercise has been shown to increase LPL and hepatic lipase activity, which stimulates TG lipolysis [123,124].”
BackgroundDelayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation
Taira, Hikita, Kobayashi, Bujo, Takahashi, Murano, Morisaki, & Saito (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00454.x · Cited by 47 · cited 1×
“Postprandial hyperlipidemia with accumulation of atherogenic remnants is especially linked to visceral obesity [75,76].”
BackgroundStructural relationship of human apolipoprotein B48 to apolipoprotein B100.
Innerarity, T. L., Young, S. G., Poksay, K. S., et al. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113273 · Cited by 47 · cited 1×
“The human liver lacks the editing complex necessary to change the apo B100 molecule into the smaller apoB48, by post-transcriptional modification of one base leading to a premature stop codon [12].”
BackgroundHalkes, C. J. M., van Dijk, H., Verseyden, C., de Jaegere, P. P. T., Plokker, H. W. M., Meijssen, S., Erkelens, D. W., & Cabezas, M. C. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000092326.00725.ed · Cited by 43 · cited 1×
“ASP/C3adesArg resistance plays a role in adequate peripheral fatty acid handling [102,106,107].”
BackgroundSelf-citationKlop, B., Jukema, J. W., Rabelink, T. J., & Cabezas, M. C. (2012) · PubMed · Cited by 42
Self-citationWang, Y., Snel, M., Jonker, J. T., Hammer, S., Lamb, H. J., de Roos, A., Meinders, A. E., Pijl, H., Romijn, J. A., Smit, J. W. A., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0685 · Cited by 41 · cited 1×
“and non-fasting TG concentrations, which can be attributed to an increase in LPL activity with a concomitant reduction in apo C-III levels [111], a decrease in CETP activity [112,113] and an increased catabolism of TG-rich lipoproteins [114].”
BackgroundFatty acids as metabolic mediators in innate immunity
Kopp, A., Gross, P., Falk, W., Bala, M., Weigert, J., Buechler, C., Neumeier, M., Schölmerich, J., & Schäffler, A. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02185.x · Cited by 40 · cited 1×
“eicosepantenoic acid, a fish oil, has anti-inflammatory properties [89–91].”
BackgroundRubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40 · cited 1×
“On the contrary, fibrates are primarily indicated in the case of hypertriglyceridemia and they reduce TG by approximately 30% and LDL-C by 8%, whereas HDL-C is increased by an average of 9% [149].”
BackgroundEffect of weight loss on C3 and C4 components of complement in obese patients
Hernández‐Mijares, A., Bañuls, C., Bellod, L., Jover, A., Solá, E., Morillas, C., Víctor, V. M., & Rocha, M. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02606.x · Cited by 40 · cited 1×
“Our group and others were able to demonstrate that the complement component 3 (C3) is one of the major determinants of the MetS [99–101] and postprandial lipemia in insulin resistant subjects, but also in insulin sensitive subjects [87,102,103].”
ResultSu, J. W., Nzekwu, M. M. U., Cabezas, M. C., Redgrave, T. G., & Proctor, S. D. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02179.x · Cited by 34 · cited 1×
“using non-physiological high amounts of fat [77].”
Self-citationSlivkoff-Clark, K. M., James, A. P., & Mamo, J. C. L. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-9 · Cited by 30 · cited 1×
“A 12-week walking program supplemented with fish oil (1000 mg eicosepantenoic acid and 700 mg docosahexaenoic acid daily) in subjects with the MetS resulted in lower fasting TG and decreased the postprandial response of TG and apoB48 [126].”
BackgroundMaraki, M. I., Aggelopoulou, N., Christodoulou, N., Anastasiou, C. A., Toutouza, M. G., Panagiotakos, D. B., Kavouras, S. A., Magkos, F., & Sidossis, L. S. (2011) · Obesity · doi:10.1038/oby.2010.218 · Cited by 30 · cited 1×
“(MUFA) resulted in a 27%–46% reduction in postprandial TG levels [117].”
BackgroundEffects of weight loss on lipid transfer proteins in morbidly obese women
Laimer, M. W., Engl, J., Tschoner, A., Kaser, S., Ritsch, A., Tatarczyk, T., Rauchenzauner, M., Weiss, H., Aigner, F., Patsch, J. R., et al. (2009) · Lipids · doi:10.1007/s11745-009-3349-8 · Cited by 28 · cited 1×
“and non-fasting TG concentrations, which can be attributed to an increase in LPL activity with a concomitant reduction in apo C-III levels [111], a decrease in CETP activity [112,113] and an increased catabolism of TG-rich lipoproteins [114].”
BackgroundCabezas, M. C., van Wijk, J. P. H., Elte, J. W. F., & Klop, B. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/394623 · Cited by 26 · cited 2×
“without any effect on catecholamine mediated lipolysis of adipocytes [108].”
BackgroundSelf-citationDifferences in the processing of chylomicron remnants and beta-VLDL by macrophages.
Ellsworth, J. L., Fong, L., Kraemer, F. B., & Cooper, A. D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42611-2 · Cited by 24
Daytime triglyceride variability in men and women with different levels of triglyceridemia
Klop, B., Cohn, J. S., van Oostrom, A. J. H. H. M., van Wijk, J. P. H., Birnie, E., & Cabezas, M. C. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.08.010 · Cited by 23 · cited 1×
“Specific treatment targets for TG levels are unavailable, especially since TG are highly variable and increase during the day [143].”
BackgroundSelf-citationWatts, G. F., Chan, D. C., Barrett, P. H. R., Martins, I. J., & Redgrave, T. G. (2001) · Clinical Science · doi:10.1042/cs1010683 · Cited by 19 · cited 1×
“Studies using stable isotopes have shown a decreased catabolism of chylomicron remnants in obese subjects with the waist/hip ratio as best predictor for the fractional catabolic rate [63].”
BackgroundKlop, B., & Cabezas, M. C. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0215-z · Cited by 18 · cited 3×
“In addition to a direct detrimental effect by chylomicron remnants on vessels [59], impaired endothelial function after an oral fat load [70] and after infusion of artificial TG-rich lipoproteins have been described [71].”
BackgroundSelf-citationPhysical Activity, Blood Lipids, and Lipoproteins
Mestek, M. L. (2009) · American Journal of Lifestyle Medicine · doi:10.1177/1559827609334885 · Cited by 18 · cited 1×
“The plasma TG lowering effect of exercise and weight loss is the most consistent finding in studies concerning blood lipids [130], whereas increasing HDL-C levels by exercise remains controversial, especially in those subjects with high TG and low HDL-C levels [131].”
BackgroundVolp, A. C. P., Barbosa, K. B. F., & Bressan, J. (2011) · Nutrition · doi:10.1016/j.nut.2011.08.014 · Cited by 17 · cited 1×
“Our group and others were able to demonstrate that the complement component 3 (C3) is one of the major determinants of the MetS [99–101] and postprandial lipemia in insulin resistant subjects, but also in insulin sensitive subjects [87,102,103].”
ResultLipoprotein profile in men with peripheral vascular disease
Baxter, B. T. (1993) · Journal of Vascular Surgery · doi:10.1016/0741-5214(93)90659-a · Cited by 17
What Combination Therapy with a Statin, If Any, Would You Recommend?
Dujovne, C. A., Williams, C. D., & Ito, M. K. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0150-3 · Cited by 17 · cited 1×
“Recently, strategies for combination therapies with statins to achieve even lower cholesterol levels have been reviewed [145–150].”
BackgroundAlipour, A., van Oostrom, A. J. H. H. M., van Wijk, J. P. H., Verseijden, C., Plokker, H. W. M., Jukema, J. W., Rabelink, T. J., & Cabezas, M. C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.007 · Cited by 16
Self-citationWatts, G. F., Chan, D. C., Ooi, E., Nestel, P., Beilin, L. J., & Barrett, P. H. R. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04458.x · Cited by 14 · cited 1×
“Omega-3 fatty acids, which decrease the hepatic synthesis and accumulation of TG [158], have been shown to reduce plasma TG by 25%–30% by effectively reducing the hepatic secretion of VLDL in insulin resistant subjects [146,159].”
BackgroundSerum Lipemia: An Overlooked Cause of Tissue Hypoxia
Engelberg, H. (2008) · Cardiology · doi:10.1159/000173604 · Cited by 13 · cited 2×
“Several investigators have demonstrated an association between TG-rich lipoproteins and remnant cholesterol levels with the presence of coronary [34–36,38–42,68], cerebral [37], and peripheral atherosclerosis [69].”
BackgroundWhy, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
Watts, G. F., & Karpe, F. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.61 · Cited by 12 · cited 1×
“Recently, strategies for combination therapies with statins to achieve even lower cholesterol levels have been reviewed [145–150].”
BackgroundThe direct way from gut to vessel wall: Atheroinitiation
Cabezas, C., & Erkelens (1998) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1998.00318.x · Cited by 11
Watts, G. F., Chan, D. C., Barrett, P. H. R., et al. (2001) · Clinical Science · doi:10.1042/cs20010166 · Cited by 10
Farewell to the metabolic syndrome? Not too soon
Cabezas, M. C., & Elte, J. W. F. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.01.012 · Cited by 2 · cited 7×
“Our group and others were able to demonstrate that the complement component 3 (C3) is one of the major determinants of the MetS [99–101] and postprandial lipemia in insulin resistant subjects, but also in insulin sensitive subjects [87,102,103].”
BackgroundInfluentialSelf-citation
Cited by
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Samson, S. L., & Garber, A. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.009 · Cited by 746
Vekic, J., Zeljkovic, A., Stefanovic, A., Jelic-Ivanovic, Z., & Spasojevic-Kalimanovska, V. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.005 · Cited by 612
Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut
Joyce, S. A., MacSharry, J., Casey, P. G., Kinsella, M., Murphy, E. F., Shanahan, F., Hill, C., & Gahan, C. G. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323599111 · Cited by 604
“Reductions of this magnitude are likely to be physiologically relevant for the mammalian host (20).”
BackgroundEffects of Exercise to Improve Cardiovascular Health
Pinckard, K., Baskin, K. K., & Stanford, K. I. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00069 · Cited by 446
Metadata
- Authors
- Klop, B., Elte, J., & Cabezas, M.
- Affiliations
- Sint Franciscus Gasthuis (NL)
- Corresponding author
- Cabezas, Manuel
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2013-04-12
- Volume
- 5
- Issue
- 4
- Pages
- 1218-1240
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC3705344
- OpenAlex
- W1985399572
- Cited by
- 1,665
- References
- 169
- Citations by year
- 2026: 90 · 2025: 157 · 2024: 194 · 2023: 210 · 2022: 196 · 2021: 195 · 2020: 138 · 2019: 117 · 2018: 76 · 2017: 74 · 2016: 75 · 2015: 63 · 2014: 65 · 2013: 12
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- obesity, dyslipidemia, metabolic syndrome, insulin resistance, small dense LDL, postprandial hypertriglyceridemia, apolipoprotein B, hepatic lipogenesis, adipose tissue inflammation, endothelial dysfunction, cardiovascular risk, lipid metabolism, obesity treatment
- MeSH terms
- Hypolipidemic Agents, Humans, Insulin Resistance, Lipids, Obesity, Risk Factors, Biomarkers, Comorbidity, Treatment Outcome, Inflammation Mediators, Caloric Restriction, Risk Reduction Behavior, Dyslipidemias, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.